163 related articles for article (PubMed ID: 36428654)
1. Clinical Efficacy of Hypofractionated Proton Beam Therapy for Intrahepatic Cholangiocarcinoma.
Kim TH; Woo SM; Lee WJ; Chun JW; Cho YR; Kim BH; Koh YH; Kim SS; Oh ES; Lee DY; Lee SU; Suh YG; Moon SH; Park JW
Cancers (Basel); 2022 Nov; 14(22):. PubMed ID: 36428654
[TBL] [Abstract][Full Text] [Related]
2. Clinical Effectiveness of Hypofractionated Proton Beam Therapy for Liver Metastasis From Breast Cancer.
Kim TH; Lee KS; Sim SH; Kim YJ; Kim DY; Chae H; Lee EG; Han JH; Jung SY; Lee S; Kang HS; Lee ES
Front Oncol; 2021; 11():783327. PubMed ID: 34804986
[TBL] [Abstract][Full Text] [Related]
3. Proton Beam Therapy for Treatment-Naïve Hepatocellular Carcinoma and Prognostic Significance of Albumin-Bilirubin (ALBI) Grade.
Kim TH; Kim BH; Park JW; Cho YR; Koh YH; Chun JW; Oh ES; Lee DY; Lee SU; Suh YG; Woo SM; Moon SH; Kim SS; Lee WJ
Cancers (Basel); 2022 Sep; 14(18):. PubMed ID: 36139604
[TBL] [Abstract][Full Text] [Related]
4. Hypofractionated proton beam radiotherapy in patients with unresectable liver tumors: multi-institutional prospective results from the Proton Collaborative Group.
Parzen JS; Hartsell W; Chang J; Apisarnthanarax S; Molitoris J; Durci M; Tsai H; Urbanic J; Ashman J; Vargas C; Stevens C; Kabolizadeh P
Radiat Oncol; 2020 Nov; 15(1):255. PubMed ID: 33148296
[TBL] [Abstract][Full Text] [Related]
5. A phase II trial of hypofractionated high-dose proton beam therapy for unresectable liver metastases.
Kim K; Yu JI; Park HC; Yoo GS; Lim DH; Noh JM; Jeong WK
Radiother Oncol; 2022 Nov; 176():9-16. PubMed ID: 36113779
[TBL] [Abstract][Full Text] [Related]
6. Proton beam stereotactic body radiotherapy and hypofractionated therapy with pencil beam scanning is safe and effective for advanced hepatocellular carcinoma and intrahepatic cholangiocarcinoma: A single center experience.
Yang AH; Urrunaga NH; Siddiqui O; Wu A; Schliep M; Mossahebi S; Shetty K; Regine WF; Molitoris JK; Lominadze Z
J Radiosurg SBRT; 2023; 9(1):43-52. PubMed ID: 38029012
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcomes and toxicity of proton beam therapy for advanced cholangiocarcinoma.
Makita C; Nakamura T; Takada A; Takayama K; Suzuki M; Ishikawa Y; Azami Y; Kato T; Tsukiyama I; Kikuchi Y; Hareyama M; Murakami M; Fuwa N; Hata M; Inoue T
Radiat Oncol; 2014 Jan; 9():26. PubMed ID: 24422711
[TBL] [Abstract][Full Text] [Related]
8. Phase II Study of Hypofractionated Proton Beam Therapy for Hepatocellular Carcinoma.
Kim TH; Park JW; Kim BH; Oh ES; Youn SH; Moon SH; Kim SS; Woo SM; Koh YH; Lee WJ; Kim DY
Front Oncol; 2020; 10():542. PubMed ID: 32411594
[No Abstract] [Full Text] [Related]
9. Proton beam therapy for unresectable intrahepatic cholangiocarcinoma.
Ohkawa A; Mizumoto M; Ishikawa H; Abei M; Fukuda K; Hashimoto T; Sakae T; Tsuboi K; Okumura T; Sakurai H
J Gastroenterol Hepatol; 2015 May; 30(5):957-63. PubMed ID: 25376272
[TBL] [Abstract][Full Text] [Related]
10. Optimal time of tumour response evaluation and effectiveness of hypofractionated proton beam therapy for inoperable or recurrent hepatocellular carcinoma.
Kim TH; Park JW; Kim BH; Kim DY; Moon SH; Kim SS; Lee JH; Woo SM; Koh YH; Lee WJ; Kim CM
Oncotarget; 2018 Jan; 9(3):4034-4043. PubMed ID: 29423102
[TBL] [Abstract][Full Text] [Related]
11. Ablative dose proton beam therapy for stage I and recurrent non-small cell lung carcinomas : Ablative dose PBT for NSCLC.
Lee SU; Moon SH; Cho KH; Pyo HR; Kim JY; Kim DY; Kim TH; Suh YG; Kim YJ
Strahlenther Onkol; 2016 Sep; 192(9):649-57. PubMed ID: 27282279
[TBL] [Abstract][Full Text] [Related]
12. Proton Beam Therapy for Intrahepatic Cholangiocarcinoma: A Multicenter Prospective Registry Study in Japan.
Mizumoto M; Terashima K; Makishima H; Suzuki M; Ogino T; Waki T; Iwata H; Tamamura H; Uchinami Y; Akimoto T; Okimoto T; Iizumi T; Murakami M; Katoh N; Maruo K; Shibuya K; Sakurai H
Liver Cancer; 2024 Apr; 13(2):161-168. PubMed ID: 38751552
[TBL] [Abstract][Full Text] [Related]
13. Chest wall toxicity after hypofractionated proton beam therapy for liver malignancies.
Yeung R; Bowen SR; Chapman TR; MacLennan GT; Apisarnthanarax S
Pract Radiat Oncol; 2018; 8(4):287-293. PubMed ID: 29452863
[TBL] [Abstract][Full Text] [Related]
14. Clinical Outcomes of Patients With Recurrent Lung Cancer Reirradiated With Proton Therapy on the Proton Collaborative Group and University of Florida Proton Therapy Institute Prospective Registry Studies.
Badiyan SN; Rutenberg MS; Hoppe BS; Mohindra P; Larson G; Hartsell WF; Tsai H; Zeng J; Rengan R; Glass E; Katz S; Vargas C; Feigenberg SJ; Simone CB
Pract Radiat Oncol; 2019; 9(4):280-288. PubMed ID: 30802618
[TBL] [Abstract][Full Text] [Related]
15. Clinical Outcomes in Patients with Recurrent Glioblastoma Treated with Proton Beam Therapy Reirradiation: Analysis of the Multi-Institutional Proton Collaborative Group Registry.
Saeed AM; Khairnar R; Sharma AM; Larson GL; Tsai HK; Wang CJ; Halasz LM; Chinnaiyan P; Vargas CE; Mishra MV
Adv Radiat Oncol; 2020; 5(5):978-983. PubMed ID: 33083661
[TBL] [Abstract][Full Text] [Related]
16. Proton beam therapy for extrahepatic biliary tract cancer: Analysis with prospective multi-institutional patients' registration database, Proton-Net.
Yamazaki H; Shibuya K; Kimoto T; Suzuki M; Murakami M; Terashima K; Okimoto T; Iizumi T; Sakurai H; Wakatsuki M; Suzuki O; Katoh N; Arimura T; Ogino T; Takagi M; Araya M; Waki T; Matsumoto S; Ogino H; Fukumoto T; Ohtsuka M
Clin Transl Radiat Oncol; 2023 Jul; 41():100634. PubMed ID: 37234735
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and feasibility of proton beam radiotherapy using the simultaneous integrated boost technique for locally advanced pancreatic cancer.
Kim TH; Lee WJ; Woo SM; Oh ES; Youn SH; Jang HY; Han SS; Park SJ; Suh YG; Moon SH; Kim SS; Kim DY
Sci Rep; 2020 Dec; 10(1):21712. PubMed ID: 33303947
[TBL] [Abstract][Full Text] [Related]
18. Hypofractionated proton beam therapy for centrally located lung cancer.
Nakamura N; Hotta K; Zenda S; Baba H; Kito S; Akita T; Motegi A; Hojo H; Nakamura M; Parshuram RV; Okumura M; Akimoto T
J Med Imaging Radiat Oncol; 2019 Aug; 63(4):552-556. PubMed ID: 31145553
[TBL] [Abstract][Full Text] [Related]
19. Phase I dose-escalation study of proton beam therapy for inoperable hepatocellular carcinoma.
Kim TH; Park JW; Kim YJ; Kim BH; Woo SM; Moon SH; Kim SS; Koh YH; Lee WJ; Park SJ; Kim JY; Kim DY; Kim CM
Cancer Res Treat; 2015 Jan; 47(1):34-45. PubMed ID: 25381830
[TBL] [Abstract][Full Text] [Related]
20. Prospective study investigating hypofractionated proton beam therapy in patients with inoperable early stage non-small cell lung cancer.
Yang K; Noh JM; Park HY; Yoo H; Shin SH; Pyo H
Front Oncol; 2024; 14():1296172. PubMed ID: 38444671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
